Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
NCT01604889 · Incyte Corporation · PHASE1/PHASE2 · terminated · last registry update 2026-04-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.” | – | Registry record, Incyte Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IDO1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-19Results posted on the registry: Thomas Jefferson University, Nivolumab + IDO1 Inhibitor BMS-986205 (NCT03854032)
- 2026-10-19Also stopped (terminated): Thomas Jefferson University, Nivolumab + IDO1 Inhibitor BMS-986205 (NCT03854032)
- 2026-07-29Also stopped (terminated): Edward Kim, IDO1 Inhibitor BMS-986205 + Nivolumab (NCT03695250)
- 2026-05-29Also stopped (withdrawn): City of Hope Medical Center, Pembrolizumab + Epacadostat (NCT03402880)
- 2026-04-20Also stopped (terminated): Incyte Corporation, Epacadostat + Atezolizumab (NCT02298153)
- 2026-04-06Results posted on the registry: Bristol-Myers Squibb, Relatlimab + Nivolumab (NCT03459222)
- 2025-10-30Also stopped (terminated): Incyte Corporation, retifanlimab + epacadostat (NCT04586244)
- 2025-10-21Also stopped (terminated): Incyte Corporation, Azacitidine + Pembrolizumab (NCT02959437)
- 2025-08-07Results posted on the registry: Washington University School of Medicine, Epacadostat + Bevacizumab (NCT03532295)
- 2025-06-08Results posted on the registry: National Cancer Institute (NCI), M7824 + N-803 (NCT03493945)
- 2025-05-02Results posted on the registry: Memorial Sloan Kettering Cancer Center, Epacadostat + Pembrolizumab (NCT03414229)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision